Home Featured Page 57

Featured

Latest

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

What You Need to Know About Massachusetts’ Question 4 and the...

Psychedelics Take Centre Stage in Massachusetts’ Local Media

Psychedelic Education Through a Healing Justice Lens

Pα+ Psychedelic Bulletin #177: Bright Minds Surges on Longboard’s Seizure Drug...

How Shadow Work Can Be a Powerful Tool for Psychedelic Transformation

The FDA, MDMA, and Public Perception: Was the FDA Fair to...

Pα+ Psychedelic Bulletin #176: Drug Developers Discuss Trial Design; Massachusetts Vote...

Protecting Indigenous Wisdom: Rethinking Psychedelic Legalization

Massachusetts Psychiatrists Push Back on Psychedelic Reform as Ballot Vote Looms:...

The Science Behind How Psychedelics Inspire Creative Breakthroughs

EDITOR PICKS

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

What You Need to Know About Massachusetts’ Question 4 and the...

Psychedelics Take Centre Stage in Massachusetts’ Local Media

Psychedelic Education Through a Healing Justice Lens

Pα+ Psychedelic Bulletin #177: Bright Minds Surges on Longboard’s Seizure Drug...

How Shadow Work Can Be a Powerful Tool for Psychedelic Transformation

The FDA, MDMA, and Public Perception: Was the FDA Fair to...

Pα+ Psychedelic Bulletin #176: Drug Developers Discuss Trial Design; Massachusetts Vote...

Protecting Indigenous Wisdom: Rethinking Psychedelic Legalization

Massachusetts Psychiatrists Push Back on Psychedelic Reform as Ballot Vote Looms:...

The Science Behind How Psychedelics Inspire Creative Breakthroughs

EDITOR PICKS

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY